Continuing Education Activity

Hyperparathyroidism secondary to chronic renal failure is a condition characterized by inappropriate secretion of parathyroid hormone (PTH), secondary to a phosphocalcic metabolic disorder. Surgical management represents the only radical treatment of the disease and its indications are well established. This activity reviews the role of the interprofessional team in the diagnosis and treatment of this condition.

Objectives:

• Identify the indications of surgery in case of secondary hyperparathyroidism.
• Outline the appropriate evaluation of secondary hyperparathyroidism.
• Review the management options available for secondary hyperparathyroidism.
• Describe interprofessional team strategies to improve care coordination for secondary hyperparathyroidism.

Access free multiple choice questions on this topic.

Introduction

Parathyroid hormone (PTH) is secreted by parathyroid glands and plays a role in calcium and skeletal metabolism.[1] Important triggers for PTH secretion are hypocalcemia and hyperphosphatemia.[2] On the other hand, the secretion of PTH is reduced by 1,25 (OH)(2) vitamin D(3).[2] Secondary hyperparathyroidism (SHPT) is an increased secretion of PTH due to parathyroid hyperplasia caused by triggers such as hypocalcemia, hyperphosphatemia, or decreased active vitamin D.[2] The increased PTH secretion, in turn, causes increased calcium in the blood by acting on bones, intestines, and kidneys.[2] 

Prolonged SHPT is often associated with disturbances of bone turnover, as well as visceral and vascular calcifications, which are responsible for cardiovascular morbidity and mortality.[3]

Despite improvements in medical treatment, surgical treatment of SHPT is often necessary, especially in refractory cases.[4] Renal transplantation is a therapeutic alternative but is frequently followed by the persistence of hyperparathyroidism.[5]

Etiology

Secondary hyperparathyroidism is commonly associated with vitamin D deficiency and chronic kidney disease (CKD).[6] The kidney cannot convert vitamin D into the physiologically active 1,25-cholecalciferol.[7] Reduced intestinal absorption of calcium resulting in a low serum calcium and elevated phosphate due to kidney's failure to excrete phosphate increases secretion of parathyroid hormone. Prolonged stimulation results in parathyroid hyperplasia.[7] SHPT also occurs in vitamin D-deficient rickets, malabsorption, and pseudohypoparathyroidism.[7]

Epidemiology

The most common causes of secondary hyperparathyroidism are vitamin D deficiency and chronic kidney disease.[6] About 50% of the world population is affected by vitamin D insufficiency.[8] CKD affects about 15% of the population in the U.S.[9] In chronic kidney disease (CKD), increased PTH levels are seen, and there is a strong correlation between the prevalence and stage of CKD, with increasing prevalence seen in advanced CKD.[7]

Pathophysiology

Hypocalcemia is the most important stimulus for increased secretion of PTH from parathyroid glands in SHPT. The increased stimulation also results in parathyroid hyperplasia. Increased PTH level results in increased calcium and phosphate absorption from the gut. PTH acts as a stimulus for increased osteoclast activity, which results in calcium and phosphorus resorption from the bone.[6] PTH activates vitamin D in the kidneys to its active form. Vitamin D increases calcium and phosphorus absorption from the gut and calcium and phosphorus reabsorption in renal tubules.[6]. Also, vitamin D suppresses PTH secretion from parathyroid glands and regulates the calcium and phosphorus levels.[6]

Fibroblast growth factor 23 (FGF-23) is secreted by osteocytes and plays an important role in phosphorus homeostasis by increasing phosphorus clearance in the renal tubules.[6] FGF-23 also inhibits 1, alpha-hydroxylase activity, and thus the active form of vitamin D.[6] FGF-23 is not known to modulate PTH secretion directly but may do so indirectly through regulating phosphate and vitamin D metabolism.[10]

In chronic kidney disease, decreasing glomerular filtration rate (GFR) leads to increased secretion of PTH. Decreasing GFR leads to decreased phosphate clearance and hyperphosphatemia, which then stimulates the parathyroid glands to secrete PTH.[11] Also, hyperphosphatemia causes hypocalcemia (phosphorus forms complexes with calcium) and stimulates FGF-23 and increased PTH secretion.[11]

Histopathology

In chronic renal failure, there is an increase in the ability of parathyroid cells to synthesize and secrete hormone, which is responsible for an increase in serum PTH concentration at first. This results in hyperplasia of the gland linked to both cell hypertrophy and increased cell proliferation, which is still potentially inhibited by therapeutic measures. As renal function deteriorates, the expression of calcium, vitamin D, and FGF23 receptors gradually decreases in the parathyroid gland, which leads to parathyroid gland hyperplasia.[12] Clones appear as nodular hyperplasia, which gives rise to true autonomic adenomas, thus causing tertiary hyperparathyroidism.[13]

Parathyroid hyperplasia is classified into four categories: diffuse hyperplasia, diffuse and multinodular hyperplasia, multinodular hyperplasia, and the simple nodular hyperplasia.[14][15]

Renal osteodystrophy comprises a group of bone mineral disorders. There are five types based on histological classification.[16]

Mild disease is a state of slightly increased bone remodeling and usually seen in early or treated SHPT.[16]

Osteitis fibrosa cystica is a state of high bone turnover from increased osteoclast activity and bone destruction and resorption caused by the high PTH levels.[11] It is characterized by peritrabecular fibrosis.[16]

Osteomalacia is the softening of the bone due to inadequate osteoid or insufficient mineralization of the osteoid, depending upon the rate of bone remodeling. The problems with mineralization arise due to abnormal calcium and phosphorus metabolism.[17]

Mixed disease has features of both osteomalacia and osteitis fibrosa and is associated with aluminum deposition [16].

Administration and overuse of vitamin D analogs, calcimimetics, and phosphate binders decrease PTH levels, which, in turn, leads to a state of low bone turnover with normal mineralization known as adynamic bone disease.[11]

History and Physical

In SHPT, the disorder of phosphocalcic metabolism will affect the different systems of the body and manifests by specific clinical signs. Primarily bone, and then soft tissues are affected. Skin can also be affected.

In SHPT, bone remodeling and mineralization are affected.[17] Bony skeletal deformities are secondary to bone remodeling.[17] This leads to bone deformation, bone pain, and bone fractures in extreme cases. Chest wall deformity and kyphoscoliosis can be noted due to abnormal mineralization and bone remodeling.[18] Pelvic bones, hip joints, and bones of lower extremities can be deformed, and increased stress from weight-bearing can lead to fractures.[18] In children, bone deformities in SHPT can lead to rickets.[19]

Extraosseous manifestations are also seen. Calcifications affect the arterial walls, viscera, periarticular tissue, cutaneous tissue, and the eye (cornea and conjunctiva). They are thus responsible for muscle weakness, red-eye syndrome, and intense pruritus.[17] Pruritis is especially seen in advanced renal disease and is due to the deposition of calcium and phosphorus on the skin. Calcifications can occur in the heart, myocardium, aortic, and mitral valves and can lead to increased cardiovascular events such as ischemia, left ventricular dysfunction, congestive heart failure, arrhythmias, and death.[20][21]

Calciphylaxis can be seen as ulceration of the skin, resulting from arterial obstruction, with cutaneous necrosis of the extremities.[17] Calciphylaxis is caused by high levels of PTH, calcium, and phosphorus induced by high levels of calcium in dialysate and phosphate binders.[18] In calciphylaxis, there is calcification of small arterioles and venules with severe intimal hyperplasia and can be complicated by thrombosis leading to painful skin necrosis.[18] Increased risk of infections, sepsis, and ischemia contributes to increased mortality risk in calciphylaxis.[18]

Other manifestations in SHPT include psychological and neurological problems, as well as malnutrition.[22]

Evaluation

Evaluation in SHPT consists of monitoring the lab values of PTH, calcium, phosphorus, vitamin D levels, and renal function.

Since it can present as bone mineral disorder and affect the musculoskeletal system, Kidney Disease for Improving Global Outcomes (KDIGO) 2017 recommends systematically performing bone mineral density in dialysis patients with bone mineralization disorders to assess the risk of pathological fracture.[23]

There are certain striking radiological features in renal osteodystrophy. Osteosclerosis is increased bone density, especially in the axial skeleton, but bone is structurally weak and prone to stress fractures.[24] "Rugger jersey" spine sign is a hallmark sign of osteosclerosis in SHPT.[25] Osteomalacia is softening of the bone due to poor mineralization of the newly formed osteoid and is characterized by the presence of looser zones on imaging.[24] 

The brown tumor in SHPT is a lytic bone lesion caused by increased osteoclastic activity and proliferation of fibroblasts.[26] On a standard radiograph, it presents itself as a well defined hypodense lesion. These tumors are located more commonly in hands, feet, facial bones, and skull.[26] Brown tumor represents the terminal stage of bone mineral disorder in secondary hyperparathyroidism.[27] Brown tumors can be misdiagnosed as neoplasms on imaging.[27]

Osteitis fibrosa cystica is revealed on standard radiographs by subperiosteal resorption, especially at the distal phalanges, clavicles, distal ulna, and skull.[25] Cortical thinning in long bones, bone cysts, and densification of the trabecular bone are also seen.[25]

Periarticular, vascular, and more rarely, visceral metastatic calcifications can also be found.[17] There are no clear guidelines regarding lab or diagnostic testing for vascular calcifications in SHPT.[28]

Treatment / Management

Medical Treatment

Management of SHPT targets abnormal phosphocalcic metabolism. Maintaining the serum calcium and phosphorus levels within the normal range along with control of PTH and vitamin D levels is the key in management of secondary hyperparathyroidism. The U.S. National Kidney Foundation (NKF) proposed the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and established targets for biomarkers (calcium, phosphorus, and PTH levels) to lower SHPT related mortality.[29] Also, the Kidney Disease Improving Global Outcomes (KDOGI) proposed clinical practice guidelines to address the management of CKD-MBD in dialysis patients.[29] However, most of these targets are difficult to achieve in the long term.

Phosphate binders, vitamin D, and calcimimetics have been reported in the management of calcium and phosphate levels in patients with CKD. In addition, patients are advised to restrict dietary intake of phosphorus by limiting phosphate-rich foods such as soda beverages, meat, cheese, and dietary products.[6] 

Phosphate binders include aluminum hydroxide, sevelamer hydrochloride, sevelamer carbonate, and lanthanum carbonate.[6] Phosphate binders can be calcium-containing or calcium-free. Calcium-containing phosphate binders are known to increase vascular and soft tissue calcification and are associated with lower survival as compared to calcium-free phosphate binders.[30]

Vitamin D metabolites include cholecalciferol (vitamin D3) and ergocalciferol, which is vitamin D2. Vitamin D analogs such as calcitriol, paricalcitol, alfacalcidol, and doxercalciferol are grouped under vitamin D receptor activators (VDRA) based on their site of action. Vitamin D could have a possible survival benefit in CKD patients.[31] Vitamin D analogs' use in CKD has been shown to decrease PTH levels and they are likely associated with reduced inflammation, decreased tubulointerstitial fibrosis, improved endothelial function, inhibition of renin-angiotensin system, prevention of vascular calcification and decreased cardiovascular outcomes, reduced hospitalizations, and improved mortality.[31] However, the majority of these findings is from observational studies, and randomized control studies are needed to validate the outcomes.[31]

Calcimimetics are agents that increase the sensitivity of calcium-sensing receptors (CaSR) in the parathyroid gland and lead to decreased PTH production. Cinacalcet is a calcimimetic drug that is commercially available and extensively used in dialysis patients. Etelcalcitide is another calcimimetic. Important side effects of calcimimetics include nausea, hypocalcemia, QT prolongation, arrhythmias, worsening heart failure, and convulsions.[6][32] Calcimimetics have been shown to suppress PTH levels but do not increase calcium or phosphorus levels.[31] Cinacalcet, along with low dose vitamin D, minimizes the risk of calcification while offering the benefits of PTH lowering therapy.[33] In Evaluation of Cinacalcet Therapy to Lower Cardiovascular Outcomes (EVOLVE) study, Cinacalcet did not improve survival or cardiovascular outcomes in dialysis patients but offered significant benefits in terms of lowering PTH, calcium, phosphate, and FGF-23 levels.[32] More RCT studies are needed to explore the full range of benefits of calcimimetics.

Surgical Treatment

Parathyroidectomy is a surgical modality available if medical therapy is unsuccessful or refractory. Other indications include calciphylaxis, refractory pruritus, severe hypercalcemia (serum calcium greater than 10.2 mg/dL) or hyperphosphatemia (serum phosphorus greater than 5.5 mg/dL), anemia hyporesponsive to erythropoietin, PTH levels more than 800 pg/mL (for more than 6 months despite medical therapy) and extraskeletal calcification.[6][34] The parathyroid glands in secondary hyperparathyroidism are characterized by asymmetric enlargement and nodular hyperplasia. Assessment of parathyroid mass is an important factor in predicting the response to medical management. Glands larger than 1 cm in size or greater than 500 mm^3 ) on ultrasound represent glandular hyperplasia and are usually refractory to medical treatment.[34] It is estimated that surgery will be required in about 15% of patients in 10 years and 38% of patients in 20 years after the initiation of dialysis.[35] Following the introduction of calcimimetics, there appears to have been a reduction in parathyroidectomy rates.[34] 

Surgical techniques include subtotal parathyroidectomy and total parathyroidectomy with or without autotransplantation.[36] Subtotal parathyroidectomy involves leaving a remnant part of the gland while total parathyroidectomy removes all the glandular tissue. Sometimes, in total parathyroidectomy, small amounts of the parathyroid gland could be autografted post-surgery. There are no major differences between subtotal parathyroidectomy and total parathyroidectomy in outcomes such as complications, readmissions, 30-day mortality.[37] However, subtotal parathyroidectomy has been associated with lower extended hospital stay post-surgery and a lower incidence of postoperative hypocalcemia.[38] Subtotal parathyroidectomy is preferred in renal transplant patients with tertiary hyperparathyroidism due to a lower risk of recurrence.[39] Total parathyroidectomy without autotransplantation is associated with a lower rate of recurrence of refractory SHPT and is preferred in patients with longer life expectancy or less likelihood of renal transplantation.[40] Total parathyroidectomy with autotransplantation is preferred for patients who cannot undergo repeat neck surgeries due to conditions such as co-existing thyroid disorders requiring surgery, history of repeated neck surgeries, recurrent laryngeal nerve injury or patients with significant perioperative comorbidities.[34]

An interesting postoperative complication of surgery is the hungry bone syndrome where the lack of osteoclastic activity causes decreased PTH, leading to hypocalcemia.[6] It can be prevented by administering high doses of calcium and using a high calcium dialysate post-surgery.[34]

Differential Diagnosis

Primary and tertiary hyperparathyroidism are always in the differential of secondary hyperparathyroidism. In primary hyperparathyroidism, there is increased secretion of PTH, which leads to increased calcium and phosphate levels.[41] In secondary hyperparathyroidism, there is hypocalcemia and hyperphosphatemia, which leads to increased PTH levels.[11]  In tertiary hyperparathyroidism, the PTH levels are excessively high, and the calcium and phosphorus levels are high as well.[11]

Pertinent Studies and Ongoing Trials

In patients on hemodialysis, Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown increased cardiovascular and all-cause mortality with calcium level greater than 10 mg/dL, phosphorus level greater than 7 mg/dL, and PTH level greater than 600 pg/ml.[42] 

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Outcomes (EVOLVE) study is the largest, double-blinded, placebo-controlled clinical trial conducted in dialysis patients with SHPT. This study showed that cinacalcet therapy did not offer survival benefit or improve cardiovascular outcomes in patients on hemodialysis.[43]

In the ADVANCE study, cinacalcet with low dose vitamin D analogs as compared to flexible vitamin D dosing showed a positive trend in decreasing vascular calcification, although the study was inconclusive.[32] 

OPTIMA study is a multicenter, open-label study that looked into cinacalcet based treatment algorithms being compared with conventional therapy in dialysis patients showed an increase in the achievement of KDOQI targets.[44]

Observational studies have shown that parathyroidectomy is beneficial in dialysis patients as it can lead to normalization of calcium and phosphorus, reduced fracture rate, improved health-related quality of life, and decreased all-cause mortality.[34] However, randomized controlled trials are lacking to validate these benefits. More prospective trials are needed to look at the outcomes of calcimimetics and parathyroidectomy.

Prognosis

Secondary hyperparathyroidism can have a significant impact on life due to complications such as bone and mineral disorders, cardiovascular complications, and calciphylaxis. Quality of life can be affected by symptoms such as muscle pain, bone pain, and fractures in extreme cases. Although medical therapy has been aimed to achieve target levels per Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, there is not much clinical evidence from prospective studies suggesting an improvement in survival due to vitamin D analogs or calcimimetics.[45] Calcimimetics have been shown to improve certain outcomes such as improvement in rates of parathyroidectomy, fractures, cardiovascular hospitalizations, and certain health-related quality of life parameters.[45] Parathyroidectomy is indicated in medically refractory disease. In ESRD patients on hemodialysis, the incidence of parathyroidectomy goes up with time, with about 15% of these patients undergoing surgery in 5 to 10 years from initiation of dialysis.[34] A study showed that parathyroidectomy, regardless of the technique used, significantly relieved most of the initial functional signs within seven days of the procedure, but patients continued to experience mild to moderate symptoms over a six-month follow-up.[46] Surgery and calcimimetics can offer improved survival in the initial stages of CKD resistance to standard therapy.[47] Surgery has not been shown to offer improved cardiovascular morbidity or mortality benefit in secondary hyperparathyroidism patients on hemodialysis.[47]

Enhancing Healthcare Team Outcomes

Secondary hyperparathyroidism is common among patients with vitamin D deficiency and chronic kidney disease. Since about half of the world population is vitamin D deficient, and about 1/7 have CKD, it is important to understand the condition in depth. Calcium, phosphorus, and vitamin D metabolism are affected in secondary hyperparathyroidism. This leads to several bone-mineralization disorders, renal osteodystrophy, and calcifications in extraosseous sites, including coronary calcifications that can lead to devastating cardiovascular outcomes and increased mortality. Thus, it is important to detect this disorder early and start therapy. Medical treatments include vitamin D analogs, calcimimetics, and phosphate binders to restore calcium, phosphorus, and the PTH levels within normal range. Early consultation with nephrologists is important to manage the outcomes. Surgery is the last option if patients do not respond to appropriate medical treatments.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Potts JT. Chemistry and physiology of parathyroid hormone. Clin Endocrinol (Oxf). 1976;5 Suppl:307S-315S. [PubMed: 802686]

2.

Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl. 2005 Jun;(95):S8-12. [PubMed: 15882315]

3.

Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017 Dec;70(6):737-751. [PubMed: 28941764]

4.

Stehman-Breen C, Muirhead N, Thorning D, Sherrard D. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis. 1996 Oct;28(4):502-7. [PubMed: 8840938]

5.

Lorenz K, Bartsch DK, Sancho JJ, Guigard S, Triponez F. Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg. 2015 Dec;400(8):907-27. [PubMed: 26429790]

6.

Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Fam Med. 2009 Sep-Oct;22(5):574-81. [PubMed: 19734404]

7.

van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S. Secondary and Tertiary Hyperparathyroidism: A Narrative Review. Scand J Surg. 2020 Dec;109(4):271-278. [PubMed: 31364494]

8.

Bouillon R, Norman AW, Lips P. Vitamin D deficiency. N Engl J Med. 2007 Nov 08;357(19):1980-1; author reply 1981-2. [PubMed: 17989396]

9.

Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015 Mar;22(2):88-95. [PubMed: 25704344]

10.

Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007 Oct;195(1):125-31. [PubMed: 17911404]

11.

Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease. Perm J. 2016 Summer;20(3):15-127. [PMC free article: PMC4991918] [PubMed: 27479950]

12.

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G., Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun;69(11):1945-53. [PubMed: 16641930]

13.

Jamal SA, Miller PD. Secondary and tertiary hyperparathyroidism. J Clin Densitom. 2013 Jan-Mar;16(1):64-8. [PubMed: 23267748]

14.

Guillem P, Vlaeminck-Guillem V, Dracon M, Noel C, Cussac JF, Huglo D, Proye C. [Are preoperative examinations useful in the management of patients with renal hyperparathyroidism?]. Ann Chir. 2006 Jan;131(1):27-33. [PubMed: 16375845]

15.

Xu D, Yin Y, Hou L, Dai W. Surgical management of secondary hyperparathyroidism: how to effectively reduce recurrence at the time of primary surgery. J Endocrinol Invest. 2016 May;39(5):509-14. [PubMed: 26620950]

16.

Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995 Jul 20;333(3):166-74. [PubMed: 7791820]

17.

Oprisiu R, Hottelart C, Ghitsu S, Said S, Westeel PF, Morinière P, el Esper N, Pruna A, Fournier A. [Renal osteodystrophy (1): invasive and non-invasive diagnosis of its pathologic varieties]. Nephrologie. 2000;21(5):229-37. [PubMed: 11068772]

18.

El-Kishawi AM, El-Nahas AM. Renal osteodystrophy: review of the disease and its treatment. Saudi J Kidney Dis Transpl. 2006 Sep;17(3):373-82. [PubMed: 16970258]

19.

JANCAR J. RICKETS WITH SECONDARY HYPERPARATHYROIDISM IN A SEVERELY SUBNORMAL CHILD. Arch Dis Child. 1963 Aug;38(200):412-4. [PMC free article: PMC2018945] [PubMed: 14058816]

20.

Wilkieson TJ, Rahman MO, Gangji AS, Voss M, Ingram AJ, Ranganath N, Goldsmith CH, Kotsamanes CZ, Crowther MA, Rabbat CG, Clase CM. Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis. Can J Kidney Health Dis. 2015;2:29. [PMC free article: PMC4534029] [PubMed: 26269747]

21.

Llach F, Fernández E. Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int Suppl. 2003 Nov;(87):S113-9. [PubMed: 14531783]

22.

Fraser WD. Hyperparathyroidism. Lancet. 2009 Jul 11;374(9684):145-58. [PubMed: 19595349]

23.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. [PMC free article: PMC6340919] [PubMed: 30675420]

24.

Chang CY, Rosenthal DI, Mitchell DM, Handa A, Kattapuram SV, Huang AJ. Imaging Findings of Metabolic Bone Disease. Radiographics. 2016 Oct;36(6):1871-1887. [PubMed: 27726750]

25.

Lacativa PG, Franco FM, Pimentel JR, Patrício Filho PJ, Gonçalves MD, Farias ML. Prevalence of radiological findings among cases of severe secondary hyperparathyroidism. Sao Paulo Med J. 2009 May;127(2):71-7. [PMC free article: PMC10964801] [PubMed: 19597681]

26.

Queiroz IV, Queiroz SP, Medeiros R, Ribeiro RB, Crusoé-Rebello IM, Leão JC. Brown tumor of secondary hyperparathyroidism: surgical approach and clinical outcome. Oral Maxillofac Surg. 2016 Dec;20(4):435-439. [PubMed: 27640197]

27.

Chew FS, Huang-Hellinger F. Brown tumor. AJR Am J Roentgenol. 1993 Apr;160(4):752. [PubMed: 8456657]

28.

Smith ER, Hewitson TD, Holt SG. Diagnostic Tests for Vascular Calcification. Adv Chronic Kidney Dis. 2019 Nov;26(6):445-463. [PubMed: 31831123]

29.

Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'? Clin Kidney J. 2018 Feb;11(1):70-72. [PMC free article: PMC5798086] [PubMed: 29423205]

30.

Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R, Ruospo M, Strippoli GF. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2016 Nov;68(5):691-702. [PubMed: 27461851]

31.

Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin d receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol. 2011;2011:419524. [PMC free article: PMC3106992] [PubMed: 21647319]

32.

Cozzolino M, Galassi A, Conte F, Mangano M, Di Lullo L, Bellasi A. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther Clin Risk Manag. 2017;13:679-689. [PMC free article: PMC5461056] [PubMed: 28615947]

33.

de Francisco AL, Carrera F. A new paradigm for the treatment of secondary hyperparathyroidism. NDT Plus. 2008 Jan;1(Suppl 1):i24-i28. [PMC free article: PMC4421151] [PubMed: 25983953]

34.

Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018 Jun 07;13(6):952-961. [PMC free article: PMC5989682] [PubMed: 29523679]

35.

Schneider R, Slater EP, Karakas E, Bartsch DK, Schlosser K. Initial parathyroid surgery in 606 patients with renal hyperparathyroidism. World J Surg. 2012 Feb;36(2):318-26. [PubMed: 22202993]

36.

Veyrat M, Fessi H, Haymann JP, Ronco P, Lacau St Guily J, Périé S. Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Apr;136(2):63-68. [PubMed: 30327179]

37.

Chen J, Jia X, Kong X, Wang Z, Cui M, Xu D. Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: A systematic review and meta-analysis. Nephrology (Carlton). 2017 May;22(5):388-396. [PubMed: 27085089]

38.

Anderson K, Ruel E, Adam MA, Thomas S, Youngwirth L, Stang MT, Scheri RP, Roman SA, Sosa JA. Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes. Am J Surg. 2017 Nov;214(5):914-919. [PubMed: 28736060]

39.

Nichol PF, Starling JR, Mack E, Klovning JJ, Becker BN, Chen H. Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg. 2002 May;235(5):673-8; discussion 678-80. [PMC free article: PMC1422493] [PubMed: 11981213]

40.

Liu ME, Qiu NC, Zha SL, Du ZP, Wang YF, Wang Q, Chen Q, Cen XX, Jiang Y, Luo Q, Shan CX, Qiu M. To assess the effects of parathyroidectomy (TPTX versus TPTX+AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis. Int J Surg. 2017 Aug;44:353-362. [PubMed: 28634117]

41.

Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016 May 19;2:16033. [PMC free article: PMC5385896] [PubMed: 27194212]

42.

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008 Sep;52(3):519-30. [PubMed: 18514987]

43.

Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007 Sep;2(5):898-905. [PubMed: 17702710]

44.

Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45. [PMC free article: PMC2390975] [PubMed: 18178780]

45.

Cunningham J, Floege J, London G, Rodriguez M, Shanahan CM. Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus. 2008 Jan;1(Suppl 1):i29-i35. [PMC free article: PMC4421154] [PubMed: 25983954]

46.

Bratucu MN, Garofil ND, Radu PA, Paic V, Goleanu V, Zurzu M, Popa F, Strambu V, Straja DN. Measurement of Quality of Life after Total Parathyroidectomy in Patients with Secondary Hyperparathyroidism and End Stage Renal Disease. Chirurgia (Bucur). 2015 Nov-Dec;110(6):511-7. [PubMed: 26713824]

47.

Conzo G, Perna AF, Savica V, Palazzo A, Della Pietra C, Ingrosso D, Satta E, Capasso G, Santini L, Docimo G. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. BMC Surg. 2013;13 Suppl 2(Suppl 2):S4. [PMC free article: PMC3851167] [PubMed: 24268127]

Disclosure: Vijayadershan Muppidi declares no relevant financial relationships with ineligible companies.

Disclosure: Sreenath Meegada declares no relevant financial relationships with ineligible companies.

Disclosure: Paul Hanna declares no relevant financial relationships with ineligible companies.

Disclosure: Anis Rehman declares no relevant financial relationships with ineligible companies.